Table 2 Studies conducted in the field of targeted drug delivery by nanobody

Oligoclonal HER2/Doxo

HER2

PEGylated liposomes /doxorubicin

Pre-clinical/

SKBR3 and BT474 cell lines

Stops the growth of cancer cells by blocking topo-isomerase 2

Farasat et al. [57]

Anti-HER2 VHH FL

Her-2

Liposome/fluorescent markers

Pre-clinical/

Her2 positive cell lines

Monitoring and tumor cell tracking

Khaleghi et al. [58]

Anti-CD19 VHH-LF

CD19

Liposomes nanoparticle/ Lethal Factor (LF) of Bacillus anthracis

Pre-clinical/

Raji B cell line

Block MAPK signaling, in the Raji B cells

Banihashemi et al. [59]

Anti-Muc1-VHH

MUC1

Chitosan

Pre-clinical/

MCF7 cell line

Inhibiting breast cancer cell growth

Khodabakhsh et al. [60]

11A4-NPs

HER2

PEGylated PLGHMGA nanoparticles/ saporin

Pre-clinical/

SKBR3 cell line

Ribosome inactivating

protein

Martinez-Jothar et al. [61]

RR2-H-RR2-lip

RR4-H-RR4-lip

HER2

HER2

Liposomes/lissamine rhodamine B sulfonyl

Pre-clinical/

BT474 and SKBR3 cell lines

Highest fluorescent intensity on HER2 breast cancer cells

Nikkhoi et al. [62]

oVHH-Lip

HER2

Liposomes /methotrexate

Pre-clinical/

BT-474 and SKBR-3 cell lines

Inhibits dihydrofolate reductase (DHFR) and prevent the tetrahydrofolate synthesis

Nikkhoi et al. [63]

11A4-CIS-NIT

HER2

Liposomes /Nitroxoline (NIT)-Cisplatin (CIS)

Pre-clinical/

TUBO cell line

NIT: inhibits cell migration by blocking cathepsin B enzyme

CIS: is used to treat various malignancy including metastatic breast cancer

Sayed-Tabatabaei et al. [64]

7D12-QD-AF

EGFR

QD (quantum-dot) micelles/AF (aminoflavone)

Pre-clinical/

MDA-MB-468 cell line

Tumor regression in breast cancer through induction of oxidative DNA damage and reactive oxidative stress

Wang et al. [65]

VHH1-FITC-PS

HER2

PEG-b-PCL/ FITC or maleimide

Pre-clinical/

SKBR-3 cell

Use in studies to evaluate the use of nanoparticles for targeted drug delivery

Zou et al. [66]